These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

724 related articles for article (PubMed ID: 7565543)

  • 21. Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.
    Jones JL; Hanson DL; Dworkin MS; Alderton DL; Fleming PL; Kaplan JE; Ward J
    MMWR CDC Surveill Summ; 1999 Apr; 48(2):1-22. PubMed ID: 12412613
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus infection in children.
    Hoernle EH; Reid TE
    Am J Health Syst Pharm; 1995 May; 52(9):961-79. PubMed ID: 7641035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protect yourself from Pneumocystis carinii.
    AIDS Alert; 1999 Jun; 14(6):suppl 1-2. PubMed ID: 11366414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Schneider MM; Borleffs JC; Stolk RP; Jaspers CA; Hoepelman AI
    Lancet; 1999 Jan; 353(9148):201-3. PubMed ID: 9923876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators.
    Yangco BG; Von Bargen JC; Moorman AC; Holmberg SD
    Ann Intern Med; 2000 Feb; 132(3):201-5. PubMed ID: 10651600
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of secondary prophylaxis for Pneumocystis pneumonia in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.
    Esposito S; Bojanin J; Porta A; Cesati L; Gualtieri L; Principi N
    Pediatr Infect Dis J; 2005 Dec; 24(12):1117-20. PubMed ID: 16371882
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
    Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
    N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing Pneumocystis carinii pneumonia in persons infected with human immunodeficiency virus.
    Simonds RJ; Hughes WT; Feinberg J; Navin TR
    Clin Infect Dis; 1995 Aug; 21 Suppl 1():S44-8. PubMed ID: 8547511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost-effectiveness of preventing AIDS-related opportunistic infections.
    Freedberg KA; Scharfstein JA; Seage GR; Losina E; Weinstein MC; Craven DE; Paltiel AD
    JAMA; 1998 Jan; 279(2):130-6. PubMed ID: 9440663
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group.
    BMJ; 1994 Feb; 308(6926):437-40. PubMed ID: 7907246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylaxis against Pneumocystis carinii pneumonia for HIV-exposed infants in Africa.
    Graham SM
    Lancet; 2002 Dec; 360(9349):1966-8. PubMed ID: 12493279
    [No Abstract]   [Full Text] [Related]  

  • 34. Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxis.
    Eigenmann C; Flepp M; Bernasconi E; Schiffer V; Telenti A; Bucher H; Wagels T; Egger M; Furrer H;
    Clin Infect Dis; 2003 Apr; 36(7):917-21. PubMed ID: 12652393
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and laboratory correlates of Pneumocystis carinii pneumonia in children infected with HIV.
    Connor E; Bagarazzi M; McSherry G; Holland B; Boland M; Denny T; Oleske J
    JAMA; 1991 Apr; 265(13):1693-7. PubMed ID: 1672168
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection.
    Gill CJ; Sabin LL; Tham J; Hamer DH
    Bull World Health Organ; 2004 Apr; 82(4):290-7. PubMed ID: 15259258
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia.
    Madhi SA; Cutland C; Ismail K; O'Reilly C; Mancha A; Klugman KP
    Clin Infect Dis; 2002 Nov; 35(9):1120-6. PubMed ID: 12384847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.